The clinical presentation of MM is not always typical of MM, but may be very similar to the presentation of AL, DLBCL, and CLL. Thus, the presence of anemia, low blood cell levels, severe anemia and hypercalcemia should raise suspicion of MM. As
A small percentage of [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) patients are eligible for myeloma-targeted therapies, a novel and highly active treatment strategy for multiple myeloma patients undergoing an operation. Patients enrolled in the trial showed survival rates and progression-free survival rates comparable to historically treated patients. ClinicalTRACT Number: NCT00016256 \n
MM is unlikely to be caused by any one factor. Rather, it is probably the result of a complex interaction of risk and protective factors. While we know some of these factors, we lack an understanding of the mechanism by which they operate. The challenge for the future may be to develop an integrated risk score with greater predictive accuracy than that of any current model. Only when such a risk score proves useful in the clinical management of a particular individual patient with MM will it be possible to recommend specific preventive or therapeutic measures that will reduce the likelihood of its clinical progression.
The goal of MM treatment is a cure. With MM's low survival and remissions with MM therapies, it is no longer an appropriate goal to cure MM. More emphasis needs to be placed on long-term disease-free survival and improving MM remission rates.
Multiple myeloma is a rare and usually curable leukemia that originates in plasma cells of bone marrow. The disease is characterized by elevated levels of serum paraprotein and hypercalcemia. Many newly diagnosed MM patients present to oncologists with a newly diagnosed bone pain and/or pathological fracture. The management of MM currently involves use of chemotherapy regimens that do not cure MM; however, some studies show improvement in quality of life.
Although less common than AL, IM and MM are a growing and serious clinical problem in the United States. Because of the recent increase in the incidence, incidence is the most important and reliable measure for evaluating the prevalence of MM in a given area.
Although the [median survival following the initiation of a bortezomib-containing regimen is around 10 months and has been shown to be effective in trials] is not as strong as previous estimates, this study demonstrates that patients may expect to survive longer than the 10 months that are typical after [bortezomib-based regimens] have been initiated. The survival rate for patients in this investigation is currently the best known survival estimate for MM patients who have been treated with a bortezomib-containing regimen (bortezomib plus dexamethasone or lenalidomide plus dexamethasone).
The time between first diagnosis and a subsequent relapse is relatively short in myelomas (8.0-10.6 months) and, in half of cases, in a third of patients with low bone destruction disease a disease-free interval seems to be achievable after a period of less than 6 months. Thus, the time between diagnosis and first observation of myeloma related events is rather short and this does not seem to be explained by the time between initial diagnosis and observation of an event. Further studies on myeloma pathogenesis are necessary to find the reasons that myeloma patients relapse.
We found limited evidence that pomalidomide has been studied in other clinical trials as compared to the current clinical trial, and it has not been found in clinical trials that could be accessed by patient/physician.
In our study population, the risk of developing multiple myeloma in the 3-to-4-year time interval preceding and following a diagnosis of monoclonal gammopathy of undetermined significance/smoldering multiple myeloma in the United States was 0.12% and 0.02%, respectively. However, no patient in this study had the typical clinical features of monoclonal gammopathy, thus, these patients likely had occult primary multiple myeloma.
The study clearly showed that pomalidomide is significantly more effective and well tolerated than a placebo. However, we are also sure that the differences in the outcome could be due to the placebo effect.
Pomalidomide can be used for multiple indications, and when used to treat more serious, chemotherapy-refractory MDS it can benefit patients with multiple myeloma. It should be used with caution in patients with lymphomas, who are at risk of developing blood clots.